EA029361B1 - Антибактериальные биароматические производные - Google Patents

Антибактериальные биароматические производные Download PDF

Info

Publication number
EA029361B1
EA029361B1 EA201501025A EA201501025A EA029361B1 EA 029361 B1 EA029361 B1 EA 029361B1 EA 201501025 A EA201501025 A EA 201501025A EA 201501025 A EA201501025 A EA 201501025A EA 029361 B1 EA029361 B1 EA 029361B1
Authority
EA
Eurasian Patent Office
Prior art keywords
oxo
ethyl
oxazin
oxooxazolidin
pyrido
Prior art date
Application number
EA201501025A
Other languages
English (en)
Russian (ru)
Other versions
EA201501025A1 (ru
Inventor
Сильвене Крен
Астрид Фридли
Кристиан Хубшверлен
Георг Рюэди
Корнелия Цумбрунн
Original Assignee
Идорсиа Фармасьютиклз Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Идорсиа Фармасьютиклз Лтд filed Critical Идорсиа Фармасьютиклз Лтд
Publication of EA201501025A1 publication Critical patent/EA201501025A1/ru
Publication of EA029361B1 publication Critical patent/EA029361B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA201501025A 2013-04-16 2014-04-15 Антибактериальные биароматические производные EA029361B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2013053021 2013-04-16
PCT/IB2014/060724 WO2014170821A1 (en) 2013-04-16 2014-04-15 Antibacterial biaromatic derivatives

Publications (2)

Publication Number Publication Date
EA201501025A1 EA201501025A1 (ru) 2016-08-31
EA029361B1 true EA029361B1 (ru) 2018-03-30

Family

ID=50639826

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201501025A EA029361B1 (ru) 2013-04-16 2014-04-15 Антибактериальные биароматические производные

Country Status (21)

Country Link
US (1) US9527867B2 (enExample)
EP (1) EP2986607B1 (enExample)
JP (1) JP6375365B2 (enExample)
KR (1) KR20150143720A (enExample)
CN (1) CN105143216B (enExample)
AR (1) AR095884A1 (enExample)
AU (1) AU2014255326B2 (enExample)
BR (1) BR112015026261A8 (enExample)
CA (1) CA2907832A1 (enExample)
CL (1) CL2015003019A1 (enExample)
EA (1) EA029361B1 (enExample)
ES (1) ES2640482T3 (enExample)
HK (1) HK1221459A1 (enExample)
MA (1) MA38588B1 (enExample)
MX (1) MX362338B (enExample)
PH (1) PH12015502411A1 (enExample)
PL (1) PL2986607T3 (enExample)
SA (1) SA515361261B1 (enExample)
SG (1) SG11201508479RA (enExample)
TW (1) TWI631119B (enExample)
WO (1) WO2014170821A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4833385B1 (ja) 2008-10-07 2011-12-07 アクテリオン ファーマシューティカルズ リミテッド 三環式オキサゾリジノン抗生物質化合物
AR102256A1 (es) * 2014-10-15 2017-02-15 Actelion Pharmaceuticals Ltd Derivados biaromáticos básicos antibacterianos con sustitución de aminoalcoxi
UY36851A (es) 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas
TW201808906A (zh) 2016-03-16 2018-03-16 拜耳作物科學股份有限公司 作為殺蟲劑之經取代吡啶化合物
AR108108A1 (es) 2016-04-14 2018-07-18 Idorsia Pharmaceuticals Ltd Derivados biaromáticos antibacterianos con sustitución de oxetan-3-iloxi
GB2550437B (en) * 2016-05-20 2021-06-23 Bugworks Res Inc Heterocyclic compounds useful as anti-bacterial agents and method for production
TW201833120A (zh) * 2017-02-17 2018-09-16 瑞士商愛杜西亞製藥有限公司 芳基噁唑啶酮抗生素化合物
EP3284739A1 (de) 2017-07-19 2018-02-21 Bayer CropScience Aktiengesellschaft Substituierte (het)arylverbindungen als schädlingsbekämpfungsmittel
CN111527093B (zh) * 2017-11-29 2023-06-09 巴格沃克斯研究有限公司 抗菌杂环化合物及其合成
MY210507A (en) 2018-08-13 2025-09-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
PH12022550339A1 (en) 2019-09-12 2023-03-13 Hoffmann La Roche 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
EP4126855B1 (en) * 2020-03-24 2024-04-24 F. Hoffmann-La Roche AG Compounds and their use in the treatment of bacterial infections
CN115785718B (zh) * 2022-11-25 2023-08-22 四川大学 一种多基底表面的金属配位抗菌涂层及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008126024A2 (en) * 2007-04-11 2008-10-23 Actelion Pharmaceuticals Ltd Oxazolidinone antibiotic derivatives
WO2010015985A1 (en) * 2008-08-04 2010-02-11 Actelion Pharmaceuticals Ltd Tricyclic alkylaminomethyloxazolidinone derivatives
WO2010041219A1 (en) * 2008-10-10 2010-04-15 Actelion Pharmaceuticals Ltd 2-benzothiophenyl-and 2-naphthyl-0xaz0lidin0nes and their azaisostere analogues as antibacterial agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0297042A1 (de) 1987-06-23 1988-12-28 Ciba-Geigy Ag Substituierte Penem-Verbindungen
DE19802239A1 (de) 1998-01-22 1999-07-29 Bayer Ag Neue mit Bicyclen substituierte Oxazolidinone
AU1026901A (en) 1999-10-29 2001-05-08 Syngenta Participations Ag Novel herbicides
AU2002347985A1 (en) 2001-11-15 2003-06-10 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
AR040335A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto
US20090186834A1 (en) 2005-03-24 2009-07-23 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
EP2141154A4 (en) 2007-03-30 2011-06-01 Inst Med Molecular Design Inc OXAZOLIDINONE DERIVATIVITY WITH HEMMETIC EFFECT ON TYPE I 11-HYDROXYSTEROIDDEHYDROGENASE
HRP20140015T1 (hr) 2007-12-20 2014-02-14 Pharma Mar, S.A. Antitumorski spojevi
BRPI0907892A2 (pt) 2008-02-20 2015-07-28 Actelion Pharmaceuticals Ltd Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
CA2713187C (en) 2008-02-22 2016-06-07 Actelion Pharmaceuticals Ltd Oxazolidinone derivatives
JP4833385B1 (ja) 2008-10-07 2011-12-07 アクテリオン ファーマシューティカルズ リミテッド 三環式オキサゾリジノン抗生物質化合物
IN2014CN04126A (enExample) 2011-11-08 2015-07-10 Actelion Pharmaceuticals Ltd

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008126024A2 (en) * 2007-04-11 2008-10-23 Actelion Pharmaceuticals Ltd Oxazolidinone antibiotic derivatives
WO2010015985A1 (en) * 2008-08-04 2010-02-11 Actelion Pharmaceuticals Ltd Tricyclic alkylaminomethyloxazolidinone derivatives
WO2010041219A1 (en) * 2008-10-10 2010-04-15 Actelion Pharmaceuticals Ltd 2-benzothiophenyl-and 2-naphthyl-0xaz0lidin0nes and their azaisostere analogues as antibacterial agents

Also Published As

Publication number Publication date
MA38588B1 (fr) 2018-04-30
KR20150143720A (ko) 2015-12-23
EP2986607B1 (en) 2017-06-14
BR112015026261A2 (pt) 2017-07-25
WO2014170821A1 (en) 2014-10-23
PL2986607T3 (pl) 2017-11-30
US20160075722A1 (en) 2016-03-17
TWI631119B (zh) 2018-08-01
AR095884A1 (es) 2015-11-18
TW201516043A (zh) 2015-05-01
EP2986607A1 (en) 2016-02-24
AU2014255326B2 (en) 2018-09-13
EA201501025A1 (ru) 2016-08-31
SA515361261B1 (ar) 2016-06-15
ES2640482T3 (es) 2017-11-03
MX2015014576A (es) 2016-03-04
JP6375365B2 (ja) 2018-08-15
BR112015026261A8 (pt) 2017-12-26
PH12015502411A1 (en) 2016-02-22
MX362338B (es) 2019-01-11
JP2016516805A (ja) 2016-06-09
US9527867B2 (en) 2016-12-27
SG11201508479RA (en) 2015-11-27
AU2014255326A1 (en) 2015-11-26
MA38588A1 (fr) 2017-05-31
CN105143216B (zh) 2018-04-13
CN105143216A (zh) 2015-12-09
CA2907832A1 (en) 2014-10-23
HK1221459A1 (zh) 2017-06-02
CL2015003019A1 (es) 2016-09-30

Similar Documents

Publication Publication Date Title
US9527867B2 (en) Antibacterial biaromatic derivatives
JP7579789B2 (ja) 免疫調節剤、組成物およびその使用方法
JP4675427B2 (ja) オレキシンレセプターアンタゴニストとしての置換ジアゼパン化合物
JP2023536948A (ja) Egfr阻害剤およびその製造方法と応用
AU2008300527B2 (en) Inhibitors of the interaction between MDM2 and p53
KR20220108070A (ko) 신규 오로라 키나아제 억제제 및 이의 용도
KR20230053639A (ko) 비시클로헵탄 피롤리딘 오렉신 수용체 효능제
CA2699707A1 (en) Inhibitors of the interaction between mdm2 and p53
US9850256B2 (en) Antibacterial basic biaromatic derivatives with aminoalkoxy substitution
CA3013927C (en) Halo-substituted piperidines as orexin receptor modulators
EP0918770A1 (en) Pyridyl-piperazinyl-phenyl-oxazolidinone derivatives and their use as antibacterials
CZ20013660A3 (cs) Substituované 3-kyano-(1,7),(1,5) a (1,8)-naftyridinové inhibitory tyrosinových kináz
AU2021410119A9 (en) Tetrahydroquinoline derivative and medicinal use thereof
JP7168245B2 (ja) 三環式化合物
AU2021261519A1 (en) 2-heteroarylaminoquinazolinone derivative
WO2016012384A1 (en) Trifluormethyloxazine amidines as bace1 inhibitors
CN119285639A (zh) Cdk9蛋白降解靶向嵌合体
JP2023063270A (ja) 2-ヘテロアリールアミノキナゾリノン誘導体からなる医薬
WO2015132141A1 (en) 1,3-oxazine-2-amine derivatives acting as bace inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU